Impact of Benfluorex Versus Metformin on Glucose Control and Insulin Secretion in Chinese Type 2 Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00544518|
Recruitment Status : Unknown
Verified May 2008 by Fourth Military Medical University.
Recruitment status was: Active, not recruiting
First Posted : October 16, 2007
Last Update Posted : May 22, 2008
Objective--- Benfluorex may have effects on the glucose control in type 2 diabetes while it improves hyperlipidemia. We sought to compare the impacts of benfluorex versus metformin on glucose control and insulin secretion in Chinese type 2 diabetic patients.
Research design and methods—--a 16-week, double-blind, multiple centers, random parallel controlled study is designed to compare the impact of benfluorex (150-450mg/day, provided by Shandong Xinhua Pharmaceutical Company Limited in China) on glucose control, insulin secretion and its safety with metformin in type 2 diabetic patients. 240 type 2 diabetic patients are to be recruited to receive benfluorex or metformin(1:1). HbA1c, plasma lipid level, insulin and glucose at 0', 30', 120' after a standard meal will be measured before and after treatment, while fasting and postprandial glucose measured 4 times regularly. The change of HbA1c from baseline to the end of treatment will taken as main efficacy criterion, as the changes of fasting and after standard meal glucose and insulin level and plasma lipid level will be taken as secondary criteria. All patient will be given safety monitor at prior and post treatment. Data management and statistical analysis will adopt DAS for Clinical Trial 2.0.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Drug: metformin Drug: benfluorex||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||240 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Study Start Date :||October 2007|
|Estimated Primary Completion Date :||September 2008|
|Estimated Study Completion Date :||October 2008|
2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
|Active Comparator: 1||
2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
- The change of HbA1c from baseline to the end of treatment [ Time Frame: 16 weeks ]
- the changes of fasting and after standard meal glucose and insulin level and plasma lipid level [ Time Frame: 16 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00544518
|XiJing hospital of Fourth Military Medical University|
|Xi'an, Shanxi, China, 710032|
|Principal Investigator:||Ji qiuhe, Ph.D||Fourth Military Medical University|